Related Experiment Video
Updated: Jul 8, 2025

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
Role of epithelial splicing regulatory protein 1 in cancer progression
1Vessel-Organ Interaction Research Center (MRC), College of Pharmacy, Kyungpook National University, Daegu, Republic of Korea. mjkwon94@knu.ac.kr.
Abstract:
As aberrant alternative splicing by either dysregulation or mutations of splicing factors contributes to cancer initiation and progression, splicing factors are emerging as potential therapeutic targets for cancer therapy. Therefore, pharmacological modulators targeting splicing factors have been under development. Epithelial splicing regulatory protein 1 (ESRP1) is an epithelial cell-specific splicing factor, whose downregulation is associated with epithelial-mesenchymal transition (EMT) by regulating alternative splicing of multiple genes, such as CD44, CTNND1, ENAH, and FGFR2. Consistent with the downregulation of ESRP1 during EMT, it has been initially revealed that high ESRP1 expression is associated with favorable prognosis and ESRP1 plays a tumor-suppressive role in cancer progression. However, ESRP1 has been found to promote cancer progression in some cancers, such as breast and ovarian cancers, indicating that it plays a dual role in cancer progression depending on the type of cancer. Furthermore, recent studies have reported that ESRP1 affects tumor growth by regulating the metabolism of tumor cells or immune cell infiltration in the tumor microenvironment, suggesting the novel roles of ESRP1 in addition to EMT. ESRP1 expression was also associated with response to anticancer drugs. This review describes current understanding of the roles and mechanisms of ESRP1 in cancer progression, and further discusses the emerging novel roles of ESRP1 in cancer and recent attempts to target splicing factors for cancer therapy.
Insights
Aberrant splicing factors drive cancer. Epithelial splicing regulatory protein 1 (ESRP1) has a dual role in cancer progression, impacting tumor growth and drug response, making it a potential therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Biology
- Pharmacology
Background:
- Aberrant alternative splicing, driven by splicing factor dysregulation or mutations, is implicated in cancer initiation and progression.
- Splicing factors are emerging as critical therapeutic targets for cancer treatment.
- Epithelial splicing regulatory protein 1 (ESRP1) is an epithelial cell-specific splicing factor involved in alternative splicing of key genes like CD44 and FGFR2.
Purpose of the Study:
- To review the current understanding of ESRP1's roles and mechanisms in cancer progression.
- To discuss the emerging novel roles of ESRP1 in cancer, including its impact on tumor metabolism and the tumor microenvironment.
- To explore recent therapeutic strategies targeting splicing factors, particularly ESRP1, for cancer therapy.
Main Methods:
- Literature review of studies investigating ESRP1's function in various cancer types.
- Analysis of research on ESRP1's association with epithelial-mesenchymal transition (EMT) and its downstream targets.
- Examination of studies exploring ESRP1's influence on tumor cell metabolism, immune cell infiltration, and drug response.
Main Results:
- ESRP1 exhibits a dual role in cancer progression, acting as a tumor suppressor in some contexts and a promoter in others (e.g., breast and ovarian cancers).
- ESRP1 downregulation is linked to EMT, while its expression levels correlate with patient prognosis and response to anticancer drugs.
- Emerging evidence suggests ESRP1 influences tumor growth through regulation of tumor cell metabolism and immune cell infiltration within the tumor microenvironment.
Conclusions:
- ESRP1 plays a complex and context-dependent role in cancer, extending beyond its known function in EMT.
- Targeting ESRP1 and other splicing factors presents a promising avenue for novel cancer therapeutic strategies.
- Further research into ESRP1's multifaceted roles in cancer biology and its interaction with the tumor microenvironment is warranted.
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Epigenetic Regulation
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

